医学
人类白细胞抗原
危险系数
胃肠病学
移植
内科学
组织相容性试验
肝移植
免疫学
抗原
置信区间
作者
Cyrille Féray,Jean‐Luc Taupin,Mylène Sebagh,Vincent Allain,Zeynep Demir,Marc‐Antoine Allard,Christophe Desterke,Audrey Coilly,Faouzi Saliba,Éric Vibert,Daniel Azoulay,Catherine Guettier,Arthur Chatton,Dominique Debray,Sophie Caillat‐Zucman,Didier Samuel
摘要
Background: The HLA evolutionary divergence (HED), a continuous metric quantifying the peptidic differences between 2 homologous HLA alleles, reflects the breadth of the immunopeptidome presented to T lymphocytes. Objective: To assess the potential effect of donor or recipient HED on liver transplant rejection. Design: Retrospective cohort study. Setting: Liver transplant units. Patients: 1154 adults and 113 children who had a liver transplant between 2004 and 2018. Measurements: Liver biopsies were done 1, 2, 5, and 10 years after the transplant and in case of liver dysfunction. Donor-specific anti-HLA antibodies (DSAs) were measured in children at the time of biopsy. The HED was calculated using the physicochemical Grantham distance for class I (HLA-A or HLA-B) and class II (HLA-DRB1 or HLA-DQB1) alleles. The influence of HED on the incidence of liver lesions was analyzed through the inverse probability weighting approach based on covariate balancing, generalized propensity scores. Results: In adults, class I HED of the donor was associated with acute rejection (hazard ratio [HR], 1.09 [95% CI, 1.03 to 1.16]), chronic rejection (HR, 1.20 [CI, 1.10 to 1.31]), and ductopenia of 50% or more (HR, 1.33 [CI, 1.09 to 1.62]) but not with other histologic lesions. In children, class I HED of the donor was also associated with acute rejection (HR, 1.16 [CI, 1.03 to 1.30]) independent of the presence of DSAs. There was no effect of either donor class II HED or recipient class I or class II HED on the incidence of liver lesions in adults and children. Limitation: The DSAs were measured only in children. Conclusion: Class I HED of the donor predicts acute or chronic rejection of liver transplant. This novel and accessible prognostic marker could orientate donor selection and guide immunosuppression. Primary Funding Source: Institut National de la Santé et de la Recherche Médicale.
科研通智能强力驱动
Strongly Powered by AbleSci AI